Congress theme: Ensuring Safety, Advancing Science: Bridging to the Future with NAMs
Provisionally accepted sessions with oral presentations, based on the ESTIV 2026 call for session.
(Notification of the acceptance/rejection of the proposal were sent on 15 May 2025)
| Beyond Positive Results: Interpreting NAMs for Endocrine Disruptors |
| Replacing the use of animals in therapeutic monoclonal antibody drug approvals |
| We Know Many of the Barriers to Adoption of NAMs, but What are the Solutions? |
| Update to OECD Guidance Document 34 on the validation of methods and Defined Approaches |
| Complex chemical mixtures across the environment-food-human continuum |
| Advancing the Use of NAMs in Food Safety: Innovations, Challenges, and Future Directions |
| Emerging researchers of the ASPIS Academy, PARC Junior Community, and VICT3R ESR |
| International Standards as the Bridge to the Future of Safe Medical Devices |
| Evolution of an OECD Test Guideline and Application Beyond; Integrated NAMs for Skin Sensitisation Hazard and Point of Departure for Risk Assessment |
| Guidance for In Vitro Air-Liquid interface Inhalation Toxicity Assessment |
| From Research to Regulation: standardising innovative non-animal technologies |
| Development and Regulatory Acceptance of NAMs in Genetic Toxicology |
| Towards robust and reliable in vitro models for Developmental and Reproductive toxicology |
| The application and standardisation of in vitro inhalation toxicology methods for academia and industry |
| NAMs in Cardiac Safety |
| Ensuring Safety of Food Nanomaterials: Bridging Microbiota to Health with NAMs. |
| State of the art of in vitro DART assays: The bigger picture |
| AI-Powered Toxicity Screening: Enhancing In Vitro Models, 3Rs, and Regulatory Adoption. |
| Advances and Challenges in the Acceptance of High Throughput Transcriptomics for Risk Assessment |
| VHP4Safety: how to move towards next-generation safety assessment based on human data? |
| Systemic Effects Evaluation Using NAM Toolboxes: Key Lessons Learned from Real-World Cases |
| Multimodal Modeling of the Gut Compartment – NAMs for Food Safety |
| Parameterization of Physiologically-based Pharmacokinetics (PBPK) Modelling for NGRA: Designed to be Protective |
ESTIV 2026 – Poster session topics
- Bio-engineering, stem cells and disease models
- Models, biomarkers and assays for endocrine disruption
- Models, biomarkers and assays for systemic and immune toxicity
- Models, biomarkers and assays for developmental toxicity
- Cardiotoxicity and cardiac efficacy models
- Local toxicity testing (safety and efficacy)
- Case studies for successful use and implementation of complex in vitro models
- Challenges in cosmetics safety
- Organ-on-a-chip & Microphysiological Systems
- Regulatory considerations for complex NAMs
- Computational toxicology – in silico modelling, read-across, artificial intelligence and machine learning
- Toxicokinetics and in vitro – in vivo extrapolation
- In vitro systems to assess respiratory toxicity
- Non-animal methods for safety testing of biopharmaceuticals/biotherapies/vaccines
- Serum free approaches
- Knowledge sharing and education
- Funding the development, validation and implementation of NAMs
- ECHA, EMA and EFSA perspectives on the use of NAMs
- In vitro and in silico methods for safety assessment of medical devices
- Role of 3R centres in the dissemination and implementation of NAMs
- Other
Draft Scientific Programme
The programme may still be subject to minor changes
Monday, June 29th, 2026
09:00-13:00: Pre-conference workshop
13:00-14:00: Lunch break
14:00-14:20: Opening Ceremony of the ESTIV 2026 Congress
Chairs: Dr Helena Kandarova (CEM SAS, Bratislava, Slovakia) & Dr Clive Roper (Roper Toxicology Consulting Limited, Edinburgh, UK)
14:20-15:00: Keynote lecture I
15:00-16:00 ESTIV Early Scientific Career Award ceremony 2026 and Lecture
Chairs: Dr Helena Kandarova (CEM SAS, Bratislava, Slovakia) & Dr Clive Roper (Roper Toxicology Consulting Limited, Edinburgh, UK)
16:00-16:30: Coffee break, visiting exhibition area & poster viewing
16:30-18:30: Session 1
18:30-20:00: Welcome reception & Poster session
Tuesday, June 30th, 2026
08:30-09:00 Keynote Lecture II
09:00-10:30: Session 2a
09:00-10:30: Session 2b
10:30-11:00: Coffee break, visiting exhibition area & poster viewing
11:00-13:00: Session 3a
11:00-13:00: Session 3b
13:00-14:00: Lunch break, visiting exhibition area & poster viewing
14:00-16:00: Session 4a
14:00-16:00: Session 4b
16:00-16:30: Coffee break, visiting exhibition area & poster viewing
16:30-17:30: Early Stage Researcher Session 1
16:30-17:30: Industry session
17:30-18:30: Early Stage Researcher Session 2
17:30-19:30: Peer Review for Validation Studies
18:30 – 19:30: ESTIV General Assembly
Poster Session
Wednesday, July 1st, 2026
08:30-09:00 Keynote Lecture III
09:00-10:30: Session 5a
09:00-10:30: Session 5b
10:30-11:00: Coffee break, visiting exhibition area & poster viewing
11:00-13:00: Session 6a
11:00-13:00 Session 6b
13:00-14:00: Lunch break, visiting exhibition area & poster viewing
14:00-15:00 Session 7a
14:00-15:00 Session 7b- Towards Liver models
15:00-16:00: Debate session and Panel discussion
16:00-16:30: Coffee break, visiting exhibition area & poster viewing
16:30-18:30: Session 8a
16:30-18:30: Session 8b
18:30 – 19:30 Career development session and poster session
19:30 – Departures to Congress dinner & social evening
Thursday, July 2nd, 2026
08:30 – 9:00 Keynote lecture IV
09:00-10:00: Session 9a
09:00-10:00: Session 9b
10:00-11:00: Session 10a
10:00-11:00: Early Stage Researcher Session 3
11:00-11:30: Coffee break
11:30-12:45: Session 11a
11:30 – 12:45: Session 11b
12:45-13:30: Congress closing ceremony
Chairs: Dr Helena Kandarova (CEM SAS, Bratislava, Slovakia) & Dr Clive Roper (Roper Toxicology Consulting Limited, Edinburgh, UK)
POST-CONFERENCE ACTIVITIES
14:00-19:00: Post-conference workshop
Friday, July 3rd, 2026
09:00-13:00: Post-conference workshop